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Abstract 
Background: Eating disorders (EDs) have been associated with alterations in cytokine concentrations 
and production. This review examines whether in vitro cytokine production (i) is altered in people with 
EDs compared to healthy participants; and (ii) changes in response to treatment? 
Methods: Using PRISMA guidelines, we systematically reviewed articles reporting group comparisons 
or longitudinal assessments of spontaneous and/or stimulated cytokine production in vitro in EDs.  
Results: Twelve studies were included. Cross-sectional results were mixed in anorexia nervosa (AN). 
Only one study measured cytokine production in bulimia nervosa. Two longitudinal studies showed that 
daily yoghurt consumption increases phytohemagglutinin-stimulated interferon-γ production in AN. 
Conclusion: The mixed results could be accounted for by variations in experimental design. Our findings 
suggest that cytokine production could possibly be modulated through dietary interventions. However, 
due to the methodological heterogeneity and shortcomings of the included studies, it seems unreasonable 
to draw further conclusions.  
Keywords: eating disorders, cytokines, anorexia nervosa, bulimia nervosa 
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1. Introduction 
Eating disorders (EDs), including anorexia nervosa (AN), bulimia nervosa (BN) and binge-eating 
disorder (BED), are characterised by disturbances in eating behaviours and body image. The aetiology 
of EDs is complex and the underlying pathophysiological mechanisms contributing to their development 
and maintenance are unclear. Alterations in immunological function and more specifically, the 
production of cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-6, have been 
implicated as a possible contributing factor. For example, recent meta-analyses have shown elevated 
levels of certain pro-inflammatory cytokines including TNF-α and interleukin IL-6 (Dalton et al., 2018; 
Solmi et al., 2015), in people with AN compared to healthy individuals. However, those with BN did 
not significantly differ in concentrations of pro-inflammatory cytokines in comparison to healthy 
volunteers and no research in BED was available to be incorporated into the meta-analyses (Dalton et 
al., 2018).  
Cytokines are soluble intercellular signalling proteins that are produced by a range of cells, including 
microglia and astrocytes, in both the brain and in the periphery (Lichtblau et al., 2013). They have 
particular importance in the immune system, but also in brain functioning (for a review see Capuron and 
Miller, 2011). It has been well documented that cytokines are involved in the regulation of appetite and 
feeding. Multiple cytokines have been shown to have inhibitory effects on food intake (Buchanan and 
Johnson, 2007; Plata-Salaman, 2001; Wong and Pinkney, 2004). For example, reductions in food intake 
have been observed following peripheral and/or central administration of interleukin (IL)-1β (Langhans 
et al., 1993) and tumor necrosis factor (TNF)-α (Bodnar et al., 1989) in animal models. In addition, in a 
validated animal model of binge-like eating behaviour, in which cycles of restriction are combined with 
frustration stress, down-regulation of the anorexigenic IL-18 system was observed (Alboni et al., 2017). 
The impact on appetite and feeding regulation is due to both direct and indirect effects of cytokines, for 
example, through interactions with orexigenic and anorexigenic neurohormones, neuropeptides, and 
neurotransmitters (e.g., Amaral et al., 2006; Romanatto et al., 2007; Wang et al., 2006), and effects on 
the central nervous system and also neurons in the hypothalamus, the ‘feeding centre’ of the brain (Plata-
Salaman et al., 1996) (Holden and Pakula, 1996). 
Cytokines have also been shown to play a mediatory role in the complex relationship between the 
immune and neuroendocrine systems. Administration of cytokines has been shown to activate the 
hypothalamic pituitary adrenal (HPA) axis, stimulating the expression and release of key hormones, 
including corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and cortisol 
(Besedovsky and del Rey, 1996; 2007). This is of particular importance in EDs as dysregulation, and 
more specifically hyperactivation, in the HPA axis has been identified (Lo Sauro et al., 2008; Warren, 
2011). Cytokines have also been shown to influence neurotransmitter synthesis, release and reuptake 
(Capuron and Miller, 2011; Holden and Pakula, 1996). This is of relevance as dysregulation in 
neurotransmitter systems, such as those related to serotonin and dopamine, have been observed in EDs 
(Kaye, 2008).  
It is also of interest that cytokines have been implicated in the pathophysiology of mental disorders that 
are highly comorbid with EDs, such as depression (Lichtblau et al., 2013) and anxiety disorders (e.g., 
generalised anxiety disorders, obsessive compulsive disorder, post-traumatic stress disorder) (Furtado 
and Katzman, 2015). Therefore, cytokines may be involved in the psychopathology associated with EDs, 
their development and maintenance (Brown et al., 2008; Corcos et al., 2003; Holden and Pakula, 1996; 
Marcos, 1997; Nova et al., 2002b; Slotwinska and Slotwinski, 2017).  
 
Cytokine production indicates an inflammatory response in the body and potential causes for cytokine 
changes in patients with EDs could include infections or a subsequent excessive use of antibiotics, 
autoimmune or autoinflammatory diseases, and the composition of the gut microbiota, as these factors 
have been found to be associated with the development of EDs (Breton et al., 2016; Morita et al., 2015; 
Morris et al., 2016; Raevuori et al., 2016; Zerwas et al., 2017). Recent reviews have focussed on 
circulating cytokine concentrations in vivo (Dalton et al., 2018; Solmi et al., 2015), therefore, there has 
been no recent collation of the evidence related to cytokine production in vitro, even though simply 
measuring plasma or serum levels of cytokines does not reflect the responsiveness of immune cells 
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following an immune challenge and thus does not provide an insight into the dynamics of an individual’s 
immune response. The current study aims to address this by conducting a systematic review of cross-
sectional and longitudinal studies assessing in vitro cytokine production across all EDs. We aim to 
provide an answer to the following two research questions: (i) is in vitro cytokine production altered in 
people with EDs compared to HCs; and (ii) does in vitro cytokine production change longitudinally in 
response to treatment interventions? 
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2. Material and methods  
This review was conducted according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). 
2.1. Selection criteria  
Studies in English of any design that assessed stimulated or un-stimulated cytokine production in vitro 
with a Diagnostic and Statistical Manual of Mental Disorders (DSM) (American Psychiatric 
Association, 1980; 2000; 2013) or International Classification of Diseases (ICD) (World Health 
Organization, 1992) diagnosis of an ED were eligible for inclusion. Publications were included if they 
reported cross-sectional comparisons of cytokine production between ED groups and healthy control 
(HC) groups or longitudinal assessments.  
Studies were excluded if: i) they assessed in vivo cytokine concentrations or genetic expression but did 
not assess cytokine production in vitro; ii) they did not report group comparisons in cytokine production 
or did not report longitudinal measurements of cytokine production;  iii) reported cross-sectional or 
longitudinal measurements without statistical comparisons between groups or across time points, 
respectively; iv) the sample was comprised of animals; or v) participants had an organic cause for their 
disordered eating e.g. cancer, immunological conditions, genetic disorder, other medical illness etc.. 
Review articles, meta-analyses, conference proceedings/abstracts, editorials, letters, book chapters, and 
unpublished theses were also not included. 
2.2. Search strategy  
Three electronic databases (PubMed, ISI Web of Science Core Collection, MEDLINE via Ovid SP) were 
searched from inception until 10th August 2018, using the following keywords and mapped to subject headings 
with the explode function where possible: “eating disorder*”, “anorexia nervosa”, bulimi*, “binge eat*” in 
combination with cytokine*, inflammat*, interleukin, interferon, IFN, “tumor necrosis factor”, TNF. Searches 
were limited to the English language. These searches were supplemented by internet searches and hand-
searches of reference lists of potentially relevant papers and reviews. Citation tracking in Google Scholar was 
also performed.  
 
Titles and abstracts of retrieved publications were imported into EndNote, duplicates were removed, 
and papers that were deemed highly unlikely to be relevant were disregarded. Full-text versions of the 
remaining articles were then obtained and screened according to the pre-specified eligibility criteria 
described above. All papers that did not meet the inclusion criteria were excluded, with the reasons 
documented (see Figure 1). The entire search process was conducted independently by two reviewers 
(B.D. and O.P.) and disagreements at the final stage were resolved by consensus.  
2.3. Data extraction  
Two reviewers (B.D. and V.W.) extracted data from all included studies into electronic summary tables, 
which were then checked by another reviewer (O.P.). Information collected related to sample 
characteristics, parameters of interest, measurement methods, and relevant findings. Given that cytokine 
measurement is affected by a range of confounding factors (e.g., age, smoking status, medication, 
concurrent physical or mental illness, menstruation) (Dugué et al., 1996), details regarding these were 
also collected and are shown in Table 1. Due to the authors’ knowledge of the area and a broad initial 
search, a narrative synthesis of the research was decided on prior to conducting the systematic search, 
given the methodological diversity of the studies. The search, screening and extraction process are 
detailed in the Supplementary File. 
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Figure 1. PRISMA flow diagram of search. 
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- No statistical 
comparison n = 1 
Studies included in 
qualitative synthesis 
n = 12 
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3. Results  
3.1. Characteristics of Included studies  
 
We identified 12 studies which met the inclusion criteria (see Figure 1 for PRISMA flow diagram), 
reporting on a total of 271 people with EDs. Nine studies reported cross-sectional comparisons in 
cytokine production between ED groups and HCs (see Table 2 for cross-sectional study details and 
findings) (Allende et al., 1998; Bessler et al., 1993; Limone et al., 2000; Nova et al., 2002a; Omodei et 
al., 2015; Polack et al., 1993; Raymond et al., 2000; Vaisman et al., 1996; Vaisman and Hahn, 1991). 
Four studies conducted longitudinal assessments of cytokine production in ED participants (see Table 
3 for longitudinal study details and findings) (Nagata et al., 1999; Nova et al., 2002a; Nova et al., 
2006; Solis et al., 2002). Only one of the included studies assessed both cross-sectional and 
longitudinal cytokine production (Nova et al., 2002a). 
 
All included studies assessed cytokine production in participants with AN. Two of these studies 
reported that their sample consisted exclusively of participants with the restricting type of AN (AN-R) 
(Nagata et al., 1999; Solis et al., 2002). Two studies reported including participants with AN-R and 
AN binge-eating/purging type (AN-BP) (Nova et al., 2002a; Nova et al., 2006). Only one study also 
assessed cytokine production in BN participants (Raymond et al., 2000). There were no studies that 
measured cytokine production in people with BED or other EDs, aside from AN and BN. ED 
diagnosis was based on the DSM-IV in 7 studies (American Psychiatric Association, 2000), the DSM-
III in 4 studies (American Psychiatric Association, 1980) or the DSM-V (American Psychiatric 
Association, 2013) in one study. The mean age (reported in 11 studies) and BMI (reported in 7 
studies) in AN participants was 17.9 ± 2.8 years and 14.9 ± 2.0 kg/m2, respectively. Illness duration of 
AN participants was reported in only two studies (Nagata et al., 1999; Nova et al., 2006) giving a 
mean illness duration of 2.7 ± 1.9 years. In the one BN study, participants had a mean age of 23.0 ± 
6.0 years and BMI or illness duration were not reported (Raymond et al., 2000). The mean age of HCs 
(reported in 6 studies: Allende et al., 1998; Bessler et al., 1993; Limone et al., 2000; Nova et al., 
2002a; Omodei et al., 2015; Raymond et al., 2000) was 20.25 ± 5.9 years and mean BMI (reported in 
4 studies: Allende et al., 1998; Limone et al., 2000; Nova et al., 2002a; Omodei et al., 2015) was in the 
healthy range: 20.8 ± 0.6 kg/m2. All participants were female, except gender was not reported in one 
study (Vaisman and Hahn, 1991). 
 
Cytokines assessed in the included studies were granulocyte-macrophage colony-stimulating factor 
(GM-CSF), interferon (IFN)-γ, IL-1α, IL-1β, IL-2, IL-3, IL-3-like activity (LA), IL-4, IL-5, IL-6, IL-
9, IL-10, IL-12p70, IL-13, IL-17α, IL-22, transforming growth factor (TGF)-β and TNF-α. Ten studies 
measured cytokine production from peripheral blood mononuclear cells (Allende et al., 1998; Bessler 
et al., 1993; Limone et al., 2000; Nova et al., 2002a; Nova et al., 2006; Omodei et al., 2015; Polack et 
al., 1993; Raymond et al., 2000; Solis et al., 2002; Vaisman and Hahn, 1991), one from mononuclear 
cells (Vaisman et al., 1996), and one from whole blood (Nagata et al., 1999). Cytokine measurement 
methods included enzyme immune-assays (9 studies: Allende et al., 1998; Limone et al., 2000; Nagata 
et al., 1999; Nova et al., 2002a; Nova et al., 2006; Raymond et al., 2000; Solis et al., 2002; Vaisman et 
al., 1996; Vaisman and Hahn, 1991), bioassay (1 study: Bessler et al., 1993) or flow cytometric 
multiplexed bead assays (1 study: Omodei et al., 2015). One study did not provide sufficient details to 
classify their measurement methods (Polack et al., 1993). All studies assessed stimulated cytokine 
production, with six studies additionally assessing spontaneous cytokine production (Allende et al., 
1998; Bessler et al., 1993; Limone et al., 2000; Nagata et al., 1999; Raymond et al., 2000; Vaisman 
and Hahn, 1991). Multiple mitogens were used to stimulate cytokine production including 
phytohaemagglutinin (PHA) (7 studies: Allende et al., 1998; Bessler et al., 1993; Nova et al., 2002a; 
Nova et al., 2006; Polack et al., 1993; Solis et al., 2002; Vaisman and Hahn, 1991), lipopolysaccharide 
(LPS) (4 studies: Bessler et al., 1993; Limone et al., 2000; Nagata et al., 1999; Vaisman and Hahn, 
1991), autologous (AS) and heterologous serum (HS) (1 study: Omodei et al., 2015), concanavalin A 
(ConA) (1 study: Raymond et al., 2000), human recombinant granulocyte-macrophage colony-
stimulating factor (rhGM-CSF) (1 study: Vaisman et al., 1996), enterotoxin A (EA) (1 study: Allende 
et al., 1998), and anti-CD3 and anti-CD28 (1 study: Allende et al., 1998). 
8 
 
 
Reporting of confounding factors (see Table 1). Age matching between ED groups and HCs was reported 
in 7 of the 9 cross-sectional studies. No studies reported on the smoking status (i.e. smoker vs. non-
smoker) of the participants. Six studies reported amenorrhea in all post-menarcheal AN participants. 
One study measured cytokines in HCs during the early the follicular phase of their menstrual cycle 
(Limone et al., 2000). Six studies did not report on menstrual status of their participants. 
Patients were confirmed medication-free in seven cross-sectional studies and for the duration of one 
longitudinal study (Nagata et al., 1999). In the three remaining longitudinal studies, participants were 
administered psychopharmacological medication as part of their inpatient treatment. Medication status 
was not reported in four studies. Three studies reported that the HCs were free from psychiatric 
disorders(Allende et al., 1998; Bessler et al., 1993; Nova et al., 2002a), with only one reporting that 
they used a standardised assessment to ensure this (Allende et al., 1998). An additional study 
confirmed that the HCs did not have a current or past history of eating disorders and that all 
participants were free of bipolar illness, psychotic disorders and substance abuse (Raymond et al., 
2000). One study reported that n=3 AN participants had a diagnosis of major depressive disorder 
(Bessler et al., 1993). 
 
With regards to physical health disorders, three studies reported that all participants were free from 
medical illness and/or were physically healthy. HCs were reported to be free from physical disorders 
in one study and AN participants were free from medical or associated illnesses in 2 studies. Five 
studies did not report on the presence or absence of medical illness in their participants(Limone et al., 
2000; Solis et al., 2002; Vaisman and Hahn, 1991). In addition, AN participants were reported to be 
free from infections, infectious diseases and/or acute signs of inflammation in 3 studies. 
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Table 1. Reporting of confounding factors in the included studies. 
Study Were 
groups age-
matched? 
Smoking 
status of 
participants 
Menstruation Medication status of 
patients 
Presence of psychiatric 
disorders 
Presence of physical 
health disorders 
Presence of infection 
or infectious disease 
Allende et al. 
(1998) 
Yes NR AN: amenorrheic 
HC: NR 
Medication free HC: free from psychiatric 
disorders 
All: free from medical 
illness 
HC: free from 
neurological conditions 
NR 
Bessler et al. 
(1993) 
Yes NR AN: amenorrheic 
HC: NR 
Medication free  HC: free from psychiatric 
disorders 
AN: n=3 diagnosis of MDD 
All: physically healthy NR 
Limone et al. 
(2000) 
NR NR AN: amenorrheic 
HC: samples collected in 
early follicular phase of 
menstrual cycle. 
Medication free NR NR NR 
Nagata et al. 
(1999) 
NA NR AN-R: amenorrheic 
HC: NR 
Medication free NR Free from medical 
illnesses and no liver or 
renal dysfunction 
Free from infectious 
disease and no signs 
of acute inflammation 
Nova et al. 
(2002a) 
Yes NR AN: amenorrheic 
HC: NR 
Medication free at baseline 
assessment. 
Medication given as part of 
inpatient treatment. 
HC: free from psychiatric 
disorders 
HC: free from physical 
disorders 
NR 
Nova et al. 
(2006) 
NA NR NR Medication given as part of 
inpatient treatment. 
NR NR NR 
Omodei et al. 
(2015) 
Yes NR NR NR NR NR AN: free from 
infectious disease 
Polack et al. 
(1993) 
Yes NR NR Medication free NR AN: free from associated 
illnesses 
NR 
Raymond et 
al. (2000) 
NR NR NR NR All: free from bipolar and 
psychotic disorders, and 
substance abuse 
HC: free from EDs 
All: free from medical 
illness 
NR 
Solis et al. 
(2002) 
NA NR NR Medication given as part of 
inpatient treatment. 
NR NR NR 
Vaisman and 
Hahn (1991) 
Yes 
 
NR NR NR NR NR NR 
Vaisman et 
al. (1996) 
Yes NR AN: post-menarchal 
participants amenorrheic 
HC: NR 
NR NR NR AN: free from 
infection 
Abbreviations:  NR = not reported; NA = not applicable; HC = healthy control; AN = anorexia nervosa; MDD = major depressive disorder; ED = eating 
disorder
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3.3. Study Findings 
3.3.1. Cross-sectional studies in anorexia nervosa (see Table 2) 
Spontaneous cytokine production. Unstimulated cytokine production was measured in 5 studies 
(Allende et al., 1998; Bessler et al., 1993; Limone et al., 2000; Raymond et al., 2000; Vaisman and 
Hahn, 1991). No differences between AN participants and HCs were observed in production of IFN-γ, 
IL-1, IL-1α, IL-3LA, IL-6, and TGF-β. One study found TNF-α production to be higher in AN 
participants to HCs (Vaisman and Hahn, 1991), however, two studies found no significant difference 
between the groups (Limone et al., 2000; Raymond et al., 2000). Similarly, IL-1β production was 
elevated in AN compared to HC participants in one study (Allende et al., 1998), but did not differ 
between groups in another study (Limone et al., 2000). 
Stimulated cytokine production. Nine studies measured stimulated cytokine production using methods. 
Findings related to stimulated IFN-γ production were mixed: two studies found no difference between 
AN participants and HCs (Nova et al., 2002a; Omodei et al., 2015), one study found elevated IFN-γ 
production (Raymond et al., 2000) and one found reduced production (Polack et al., 1993) in AN 
participants compared to HCs. 
AN participants and HCs did not differ in IL-1 production in two studies (Bessler et al., 1993; Vaisman 
et al., 1996). Two studies found participants with AN to have higher stimulated IL-1β production than 
HCs (EA and anti-CD3 only, Allende et al., 1998; Nova et al., 2002a) and two studies found no 
difference between AN and HC groups (Limone et al., 2000; Omodei et al., 2015). Three studies 
identified no difference in IL-2 stimulated production between AN and HC groups (Allende et al., 1998; 
Nova et al., 2002a; Omodei et al., 2015). One study found lower production in AN compared to HCs 
(Bessler et al., 1993). Stimulated IL-6 production did not differ between AN and HC participants in 3 
studies (AS only, Omodei et al., 2015; Raymond et al., 2000; Vaisman et al., 1996). One study found 
lower levels of production in AN participants (Nova et al., 2002a) and one found higher (HS only, 
Omodei et al., 2015) compared to HCs. 
The majority of studies found no difference in stimulated TNF-α production between AN and HC 
participants (Limone et al., 2000; Omodei et al., 2015; Raymond et al., 2000; Vaisman and Hahn, 1991); 
however, one study found lower stimulated TNF-α production in AN participants compared to HCs 
(Nova et al., 2002a). 
Stimulated production of several other cytokines were assessed in only one study, including IL-1α, IL-
4, IL-5, IL-9, IL-10, IL-12p70, IL-13, IL-17α, IL-22 and TGF-β and were found to not differ between 
AN participants and HCs (Omodei et al., 2015; Raymond et al., 2000). GM-CSF (Vaisman et al., 1996) 
and IL-3 (Allende et al., 1998) stimulated production were also reported in only one study and were 
found to be reduced in AN compared to HC participants. 
3.3.2. Cross-sectional studies in bulimia nervosa (see Table 2) 
In the only study to assess cytokine production in people with BN, both unstimulated and ConA-
stimulated production of IFN-γ, IL-1α, IL-6 and TNF-α did not significantly differ between BN 
participants and HCs. 
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Table 2. Study characteristics and findings from in vitro cross-sectional studies. 
Study N Sample Mean age 
± SD 
(years) 
Mean 
BMI ± 
SD 
(kg/m2) 
Diagnostic 
criteria 
Parameters 
of interest 
Mitogen used Measurement method Findings 
Spontaneous 
cytokine 
production 
Stimulated 
cytokine 
production 
Additional 
findings 
Studies in anorexia nervosa 
Allende 
et al. 
(1998) 
54 Female AN 
(n=40)  
Female HC 
(n=14) 
16.8 ± 2.3 
15.7 ± 1.2 
17.8 ± 
1.6 
20.6 ± 
1.5 
DSM-IV IL-1β, IL-2, 
IL-3 
EA 1 ng/ml  
PHA 1:100 final 
dilution 
Anti-CD3 12.5 
ng/ml 
Anti-CD28 50 
ng/ml 
PBMCs - ELISA IL-1β: 
AN>HC 
IL-1β: 
AN>HC 
(EA, anti-
CD3 only); 
AN=HC 
(anti-CD28, 
PHA only) 
IL-2: 
AN=HC 
IL-3: 
AN<HC 
(anti-CD3, 
anti-CD28 
only) 
 
Bessler et 
al. (1993) 
20 Female AN 
(n=10) 
Female HC 
(n=10) 
17.6 ± 1.6 
17.8 ± 0.6 
NR 
NR 
DSM-III IL-1, IL-2, 
IL-3-LA 
IL-1: LPS 10 
µg/mL  
IL-2: PHA 1 
µg/mL  
PBMCs - bioassay IL-1, IL-
3LA: 
AN=HC 
IL-1: 
AN=HC 
IL-2: 
AN<HC 
 
Limone 
et al. 
(2000) 
26 Female AN 
(n=13) 
Female HC 
(n=13) 
18.0 ± 2.1 
19.0 ± 1.8 
12.9 ± 
1.7 
21.7 ± 
1.8 
DSM-IV IL-1β, 
TNF-α 
LPS 10 µg/mL  PBMCs - enzyme 
immunoassay 
AN=HC AN=HC In AN, 
unstimulated IL-
1β production 
positively 
correlated with 
serum cortisol 
levels. 
Nova et 
al. 
(2002a) 
72 Female AN 
(n=37) 
Female HC 
(n=35) 
15.8 ± 1.5 
15.4 ± 1.3 
15.4 ± 
1.4 
20.6 ± 
2.7 
DSM-IV IFN-γ, IL-2, 
TNF-α, IL-
6, IL-1β 
PHA 7 pg/ml  PBMCs - ELISA  IFN-γ, IL-2: 
AN=HC 
TNF-α, IL-
6: AN<HC 
IL-1β: 
AN>HC 
Illness duration 
correlated with 
IL-1β (negative) 
and IFN-γ 
(positive) 
production. 
Omodei 
et al. 
(2015) 
35 Female AN 
(n=15) 
19.7 ± 3.8 
22.6 ± 3.7 
16.0 ± 
1.6 
DSM-V TNF-α, 
IFN-γ, IL-
1β, IL-2, 
Autologous 
serum (AS) 
PBMCs - Human 
Th1/Th2/Th9/Th17/Th22 
13plex kit FlowCytomix 
 IL-6 (HS 
only): 
AN>HC 
 
12 
 
Female HC 
(n=20) 
20.4 ± 
3.1 
IL-4, IL-5, 
IL-6, IL-9, 
IL-10, IL-
12p70, IL-
13, IL-17α, 
IL-22 
Heterologous 
serum (HS) 
TNF-α, 
IFN-γ, IL-
1β, IL-2, 
IL-4, IL-5, 
IL-6 (AS 
only), IL-9, 
IL-10, IL-
12p70, IL-
13, IL-17α, 
IL-22: 
AN=HC  
Polack et 
al. (1993) 
60 Female AN 
(n=30) 
Female HC 
(n=30) 
16.5 ± 2.1 
NR 
NR 
NR 
DSM-III IFN-γ PHA 10 µg/mL  PBMC – Measurement 
of antiviral activity of 
IFN-γ  
 AN<HC After 18-months 
of treatment, in 
2/4 AN 
participants, IFN-
γ production 
AN=HC. 
Raymond 
et al. 
(2000) 
42 Female AN 
(n=19) 
Female HC 
(n=23) 
23.0 ± 8.0 
31.0 ± 9.0 
NR 
NR 
DSM-IV IL-6, IFN-γ, 
IL-1α, 
TNF-α, 
TGF-β 
ConA 12.5 
mg/ml  
PBMC - ELISA AN=HC IFN-γ: 
AN>HC 
IL-6, IL-1α, 
TNF-α, 
TGF-β: 
AN=HC 
 
 
Vaisman 
and 
Hahn 
(1991) 
23 AN (n=7) 
HC (n=16) 
15.1 ± 1.4 
NR 
NR 
NR 
DSM-III TNF-α LPS 10 µg/mL 
PHA 20 µg/mL  
PBMC - ELISA AN>HC AN=HC During refeeding, 
spontaneous and 
induced TNF-α 
production 
gradually 
decreased. 
Vaisman 
et al. 
(1996) 
17 Female AN 
(n=10) 
Female HC 
(n=7) 
15.8 ± 1.6 
NR 
NR 
NR 
DSM-III IL-1, IL-3, 
IL-6, GM-
CSF, TNF 
rhGM-CSF 10 
ng/mL 
MNC - ELISA 
 
 IL-1, IL-6: 
AN=HC 
GM-CSF: 
AN<HC  
IL-3, TNF: 
ND 
 
Studies in bulimia nervosa 
Raymond 
et al. 
(2000) 
39 Female BN 
(n=16) 
Female HC 
(n=23) 
23.0 ± 6.0 
31.0 ± 9.0 
NR 
NR 
 IL-6, IFN-γ, 
IL-1α, 
TNF-α, 
TGF-β 
ConA 12.5 
mg/ml  
PBMC - ELISA BN=HC BN=HC  
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Abbreviations: N = number of subjects; SD = standard deviation; BMI = body mass index; AN = anorexia nervosa; HC = healthy control; DSM = Diagnostic 
and Statistical Manual of Mental Disorders; IL = interleukin; EA = enterotoxin A; PHA = phytohaemagglutinin; PBMC = peripheral blood mononuclear cell; 
ELISA = enzyme-linked immunosorbent assay; NR = not reported; LA = like activity; LPS = lipopolysaccharide; TNF = tumor necrosis factor; IFN = 
interferon; TGF = transforming growth factor; ConA = concanavalin A; GM-CSF = granulocyte-macrophage colony-stimulating factor; rhGM-CSF = human 
recombinant granulocyte-macrophage colony-stimulating factor; MNC = mononuclear cells; BN = bulimia nervosa.
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3.3.3. Longitudinal studies in anorexia nervosa (see Table 3) 
The four studies measuring cytokine production longitudinally differed significantly in intervention 
type. Firstly, two assessed cytokine changes in response to inpatient treatment (Nagata et al., 1999; Nova 
et al., 2002a). Nagata et al. (1999) found that LPS-stimulated production of IFN-γ, IL-1α, IL-1β, IL-6 
and TNF-α increased as a function of weight gain, whereas G-CSF production remained stable at all 
time points. In contrast, Nova et al. (2002a) found that PHA-stimulated production of IFN-γ, IL-1β, IL-
2, IL-6 and TNF-α did not differ between admission and discharge from inpatient treatment. 
Secondly, the remaining two studies conducted randomised controlled trials assessing the impact of 
dairy product consumption (yoghurt vs. milk) on cytokine production during inpatient treatment (Nova 
et al., 2006; Solis et al., 2002). Both studies found that 10-weeks of daily yoghurt (containing 
lactobacillus delbrueckii subsp. bulgaricus and streptococcus thermophilus) consumption increased 
PHA-stimulated IFN-γ production. In response to milk consumption, IFN-γ production reduced in both 
studies. However, if participants had firstly engaged in yoghurt consumption for 10-weeks, milk had no 
effect on IFN-γ production (Solis et al., 2002). Other cytokines also measured (IL-1β, IL-2, IL-6, TNF-
α) remained stable throughout the intervention (Nova et al., 2006). It is important to note that weight 
gain in AN participants was observed in both studies, regardless of dietary intervention. 
3.3.3. Longitudinal studies in bulimia nervosa 
No studies investigated cytokine production longitudinally using in vitro methods in BN. 
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Table 3. Study characteristics and findings from in vitro longitudinal studies. 
Study N Sampl
e 
Mean 
age ± 
SD 
(years
) 
Mean 
BMI ± 
SD 
(kg/m2
) 
Diagnosti
c criteria 
Intervention Assessmen
t time 
points 
Paramete
rs of 
interest 
Mitoge
n used 
Measureme
nt method 
Findings 
Spontaneo
us cytokine 
production 
Stimulate
d 
cytokine 
productio
n 
Additional 
findings 
Studies in anorexia nervosa  
Nagat
a et al. 
(1999) 
1
7 
Femal
e AN-
R 
 
22.7 ± 
6.1 
 
11.6 ± 
1.3 
 
DSM-IV Inpatient 
treatment 
T1: At 
admission 
(<60% 
SBW) 
T2: At 65% 
SBW 
T3: At 75% 
SBW 
IL-1α, IL-
1β, IL-2, 
Il-6 TNF-
α, G-CSF, 
IFN-γ 
LPS 10 
µg/mL  
Whole blood 
- ELISA 
ND IFN-γ, IL-
1α, IL-1β, 
Il-6, TNF-
α: T0>T1, 
T0>T2 
G-CSF: 
T0=T1=T
2 
IL-2: ND 
No 
significant 
correlations 
between 
cytokine 
production 
and 
demographi
c or clinical 
variables. 
Nova 
et al. 
(2002a
) 
3
7 
Femal
e AN 
 
15.8 ± 
1.5 
 
15.4 ± 
1.4 
 
DSM-IV Inpatient 
multidisciplina
ry treatment 
T0: At 
admission 
T1: At 
discharge 
IFN-γ, IL-
2, TNF-α, 
IL-6, IL-
1β 
PHA 7 
pg/ml  
PBMCs - 
ELISA 
 T0=T1 IFN-γ, IL-
6, TNF-α: 
T1<HC 
IL-2: 
T1=HC IL-
1β: T1>HC 
Nova 
et al. 
(2006) 
3
0 
Femal
e AN 
 
16.1 ± 
1.9 
15.1 ± 
1.7 
DSM-IV AN-m (n=14): 
consumed 400 
ml/day of milk 
for 10 weeks  
AN-y (n=16): 
consumed 375 
g/day of 
yoghurt for 10 
weeks 
T0: At 
admission 
T1: After 6 
weeks of 
dairy 
product 
consumptio
n 
T2: After 
10 weeks 
of dairy 
product 
IFN-γ, IL-
2, IL-6, 
IL-1β, 
TNF-α 
PHA 10 
µg/mL  
 
PBMCs - 
ELISA 
 IFN-γ: 
AN-m 
T0>T2, 
AN-y 
T0<T2  
IL-2, IL-6, 
IL-1β, 
TNF-α: 
T0=T2 
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consumptio
n 
Solis 
et al. 
(2002) 
2
7 
Femal
e AN-
R 
 
NR 15.4 ± 
1.6 
DSM-IV AN1 (n=16): 
consumed 375 
g/day of 
yoghurt for 10 
weeks, 
followed by 
450 g/day of 
milk for 10 
weeks 
AN2 (n=11): 
consumed 450 
g/day of milk 
for 10 weeks, 
followed by 
375 g/day of 
yoghurt for 10 
weeks 
T0: 
Baseline 
T1: Week 6 
T2: Week 
10 
T3: Week 
16 
T4: Week 
20 
IFN-γ PHA PBMCs - 
ELISA 
 AN1: 
T0<T2, 
T0<T4, 
T2=T4 
AN2: 
T0>T2, 
T0=T4, 
T2<T4 
 
Abbreviations: N = number of subjects; SD = standard deviation; BMI = body mass index; AN-R = anorexia nervosa restricting type; HC = healthy control; 
DSM = Diagnostic and Statistical Manual of Mental Disorders; T = time point; IL = interleukin; TNF = tumor necrosis factor; G-CSF = granulocyte-colony 
stimulating factor; IFN = interferon; LPS = lipopolysaccharide; ELISA = enzyme-linked immunosorbent assay; ND = not detected; AN = anorexia nervosa; 
PHA = phytohaemagglutinin; PBMC = peripheral blood mononuclear cell; NR = not reported 
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4. Discussion 
This systematic review summarises and integrates the existing data on spontaneous and stimulated 
cytokine production across EDs. All studies reported on findings in AN, with only one study also 
measuring cytokine production in people with BN (Raymond et al., 2000). No studies reported on 
cytokine production in BED or other EDs. While a broad range of cytokines were measured, few 
cytokines were measured across multiple studies. Limited assessments in BN and of certain cytokines 
across multiple studies, in combination with the heterogeneity in the study samples, design, and 
methodologies, precludes definitive conclusions on the relationship between cytokine production and 
EDs. 
4.1. Findings in anorexia nervosa 
Cross-sectional studies. Findings were inconsistent across studies in relation to spontaneous and 
stimulated production of the following cytokines: IFN-γ, IL-1β, IL-2, Il-6 and TNF-α. Most studies 
found no difference between AN participants and HCs, however, a few studies identified reductions 
and/or elevations in the production of these cytokines in people with AN compared to HCs. Other 
cytokines (IL-1α, IL-3, GM-CSF, TGF-β) were only assessed in individual studies and therefore, 
conclusions cannot be drawn. Across two studies IL-1, a potent anorexigenic pro-inflammatory 
cytokine (Wong and Pinkney, 2004), was found to consistently not differ between people with AN and 
HCs (Bessler et al., 1993; Vaisman et al., 1996).  
 
Previous studies have identified similar inconsistent findings in circulating concentrations of these 
cytokines (e.g., Allende et al., 1998; Brambilla et al., 2001; Nogueira et al., 2010; Ostrowska et al., 
2015). Although, when taken together, recent meta-analyses found elevated levels of the pro-
inflammatory cytokines IL-6 and TNF-α in AN participants compared to HCs (Dalton et al., 2018; Solmi 
et al., 2015). However, it is important to note that circulating levels of cytokines measured in vivo in 
patients with EDs are influenced by ED-associated behaviours and subsequent biological processes. In 
AN, for example, leptin, cortisol and ghrelin are altered as a consequence of self-starvation (Himmerich 
et al., 2010) and these hormones have been shown to have effects on the immune system (Himmerich 
and Sheldrick, 2010). Therefore, an in vitro approach, using purified immune cells, may be more suitable 
to examine the function of the immune system without the influence of the metabolic changes which are 
a consequence of the ED. In order to investigate whether the immune system may be causally involved 
in the development of an ED, it seems sensible to perform immunological studies, where the metabolic 
implications of the ED are neutralised as much as possible. 
Research in other psychiatric disorders, including depression, schizophrenia and post-traumatic stress 
disorder, has found that symptom severity and other clinical characteristics (e.g., illness duration, age 
of onset) are associated with cytokine levels (Dunjic-Kostic et al., 2013a; Dunjic-Kostic et al., 2013b; 
Gill et al., 2008). In one included study, illness duration was found to negatively correlate with IL-1β 
production and positively with IFN-γ (Nova et al., 2002a). However, in Nagata et al. (1999) clinical 
variables did not significantly correlate with cytokine production. More studies in EDs are needed to 
examine the relationship between cytokines and clinical characteristics.  
There are several methodological factors that may account for the conflicting findings, including small 
samples, diverging experimental designs and cytokine measurement methods, and confounding 
factors. With regards to the measurement method, a variety of mitogens, cell types and assays were 
used. In vitro cytokine production can be differentially affected depending on the mitogen used (Ai et 
al., 2013; Allende et al., 1998), which given the variety of stimulants used across the include studies, 
may limit the comparability of studies and also may account for the mixed results. In addition, the 
procedures used to extract PBMCs from the rest of the blood may wash out important plasma 
molecules and thus disrupt molecular networks between immune cells; therefore, data on cytokine 
production derived from the use of PBMCs outside the blood environment may not reflect how 
PBMCs would respond in vivo (Ai et al., 2013). Ultimately, due to variation in experimental design 
and a lack of standard values, there is a difficulty in interpreting in vitro study results. In order to 
implement these normal limits, the experimental design needs to become standardised. This could 
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involve standardised blood drawing procedures, a standardised method of immunological stimulation 
and incubation of the cells, and a generally accepted method for the measurement of cytokines. 
 
Our review of confounding variables in the included studies (see Table 1) highlighted that several 
important pre-analytical factors had not been incorporated into the design and/or analysis of the 
studies, including smoking, medication status, and presence of concurrent physical and mental 
illnesses (Dugué et al., 1996). For example, none of the included studies reported participant’s 
smoking status even though smoking is known to alter cytokine production (Petrescu et al., 2010) and 
to also influence the gut microbiota (Benjamin et al., 2012) which, in turn, modulates cytokine 
signalling (Haase et al., 2018). Additionally, in the majority of studies, co-morbid psychiatric 
conditions in the AN participants were not assessed, despite alterations in cytokine levels being 
identified in disorders such as depression (Lichtblau et al., 2013) and anxiety (Baldwin et al., 2017). 
Similarly, only one study reported using a standardised assessment to ensure the absence of 
psychiatric disorders in their HC group (Allende et al., 1998). Therefore, we cannot rule out the 
possibility that psychiatric conditions contributed to the results observed in the included studies. 
Furthermore, not all studies screened their participants for autoimmune and autoinflammatory 
diseases. Given that excessive, reduced, or aberrant cytokine responses contribute to the pathogenesis 
of these illnesses (Moudgil and Choubey, 2011) and autoimmune and anti-inflammatory diseases have 
been shown to be associated with an increased risk for EDs (Raevuori et al., 2014; Zerwas et al., 
2017), future studies need to ensure all participants are assessed for the presence of these diseases.  
 
Longitudinal studies. Contradictory findings between two longitudinal studies assessing cytokine 
production in inpatient treatment settings were found: Nagata et al. (1999) found that stimulated 
production of IFN-γ, IL-1α, IL-1β, IL-6 and TNF-α increased and Nova et al. (2002a) found that 
production of IFN-γ, IL-1β, IL-2, IL-6 and TNF-α remained stable over time. The final assessment point 
was different in each of these studies, with one focusing on meeting certain weight targets, specifically 
when 75% of SBW was reached (Nagata et al., 1999), and the other basing the timing of the follow-up 
assessment on discharge from the inpatient hospital, for which both weight recovery and psychological 
evaluation were taken into consideration (Nova et al., 2002a). Variance in the inpatient treatment 
received by participants may have also contributed to the observed findings: in Nagata et al. (1999) 
treatment was focused around refeeding with some cognitive-behavioural treatment and no medication, 
whereas in Nova et al. (2002a) psychopharmacological medication was additionally provided. 
Psychotropic medication (e.g., antidepressants, antipsychotics) has been shown to influence cytokine 
production (Himmerich et al., 2011; Munzer et al., 2013) and therefore, may have contributed to the 
results observed in Nova et al. (2002a). 
Both dietary intervention trials found that daily yoghurt consumption for 10-weeks increased IFN-γ 
production (Nova et al., 2006; Solis et al., 2002). However, other cytokines (IL-1β, IL-2, IL-6, TNF-α) 
were not found to change as a result of the intervention (Nova et al., 2006). The authors suggest that 
potential beneficial effects of increased IFN-γ on the immune response could be presumed, given that 
previous studies have indicated inhibition of PHA-induced IFN-γ production in people with AN 
compared to HCs (Polack et al., 1993; Schattner et al., 1990). However, these studies are not capable of 
proving that an increase in IFN-γ would ameliorate immune defence in AN patients. The authors are 
also unclear on how cytokine production is modulated by yoghurt consumption. As the lactic acid 
bacteria contained in the yoghurt used in the interventions (lactobacillus delbrueckii subsp. bulgaricus 
and streptococcus thermophilus) has been shown to have little to no viability in the human gut and a 
limited ability to influence the composition of the gut microbiota (Pei et al., 2017), more research is 
needed to determine the mechanisms by which yoghurt influences cytokine production. It is important 
to consider that the translation of in vitro findings to in vivo implications is difficult, therefore, we cannot 
be sure that these studies are proof-of-concept that it is possible to modify cytokine production in people 
with AN through a simple dietary intervention. Future research should focus on whether these and other 
interventions, particularly those currently being researched in the treatment of EDs (e.g., psychological 
therapy, brain stimulation, cognitive bias modification), have the ability to modulate concentrations of 
circulating cytokines.  
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None of the longitudinal studies reported standardised assessments of ED symptoms at the various time 
points cytokine production was assessed. This therefore precludes any examination of whether 
longitudinal changes in cytokine production are associated with the psychological symptoms of the ED 
or weight gain. Future research should ensure assessment of ED severity at all time points to allow for 
examination of this and determine whether cytokines are a marker of treatment response.  
4.2. Findings in bulimia nervosa 
Only one study measured cytokine production in people with BN, identifying no differences between 
BN participants and HCs in spontaneous or stimulated production of IFN-γ, IL-1α, IL-6 and TNF-α 
(Raymond et al., 2000). These findings are similar to that observed in two studies that measured cytokine 
concentrations in vivo (Brambilla et al., 1998; Monteleone et al., 1999). Although concentrations of IL-
6 and TNF-α have also been found to be elevated in people with BN, compared to HCs in two studies 
(Ahren-Moonga et al., 2011; Nakai et al., 2000). Binge eating behaviours (as assessed by a range of 
questionnaires) have also been shown to be significantly and positively associated with TNF-α 
concentrations in adolescents (Lofrano-Prado et al., 2011). Ultimately few studies have considered the 
role cytokines play in BN and also binge eating behaviours more specifically. This highlights the need 
for future studies to measure cytokines across EDs presenting with binge-eating behaviours i.e. BN, 
BED and AN-BP. 
 
4.3. Conclusions 
Given the contradictory findings presented in the current review, it is unclear whether ED participants 
differ in cytokine production in comparison to HCs. This variation in findings could be accounted for 
by various methodological issues highlighted in this review, such as limited reporting and 
consideration of confounding factors in the measurement of cytokines, the variability in equipment 
and methods used to measure cytokines, and small sample sizes. Given the identified methodological 
heterogeneity and shortcomings of the included and evaluated in vitro studies, it seems unreasonable 
to draw far-reaching conclusions from their results. Only one study assessed cytokine production in 
BN (Raymond et al., 2000) and no studies considered cytokine production in other EDs, such as binge 
eating disorder. This highlights the need for more research in these patient groups. 
The findings of the longitudinal studies assessing cytokines production in AN during inpatient 
treatment were also mixed (Nagata et al., 1999; Nova et al., 2002a). This could be due to confounding 
factors of medication, weight gain, and variability in treatment. However, two longitudinal studies 
found that IFN-γ production increased in response to a dietary intervention (Nova et al., 2006; Solis et 
al., 2002). Therefore, evidence from these studies indicates that it may be possible to influence in vitro 
IFN-γ production in people with AN, however, more evidence is needed to support such a conclusion. 
Future research would benefit from measuring cytokine production alongside psychological 
assessments over the treatment course to gain a clearer understanding of how cytokines are related to 
treatment response and their association with both psychological and weight changes. Furthermore, 
longer-term research studies may help to elucidate the role of cytokines in EDs and to determine 
whether augmented cytokine production are state or trait marker of EDs. 
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